Progress of research on combined drug therapies for treatment of methicillin-resistant Staphylococcus aureus infection
10.11816/cn.ni.2025-241435
- VernacularTitle:联合用药治疗耐甲氧西林金黄色葡萄球菌感染的研究进展
- Author:
Yixuan TIAN
1
;
Qianhong YE
1
Author Information
1. 澳门理工大学健康科学及体育学院,澳门特别行政区 999078
- Publication Type:Journal Article
- Keywords:
Methicillin-resistant Staphylococcus aureus;
Antimicrobial agent;
Drug combination;
Progress of re-search;
Traditional Chinese medicine;
Nanotechnology
- From:
Chinese Journal of Nosocomiology
2025;35(13):2068-2073
- CountryChina
- Language:Chinese
-
Abstract:
Methicillin-resistant Staphylococcus aureus(MRSA)is a super drug-resistant pathogen for its multi-drug resistance,strong pathogenicity,high morbidity and mortality and is common in communities and hospi-tals in recent years.With the extensive use of various broad-spectrum antibiotics and the abuse of antimicrobial a-gents,MRSA strains have shown extensive resistance to conventional antibiotics such as vancomycin in recent years.The development of new drugs and new therapeutic regimens is the major clinical task for treatment of MR-SA infection.Enhancing the antimicrobial effect of traditional antibiotics and reducing the resistance through com-bined usage of drugs are at present the feasible measures for clinical treatment.The article focuses on the drug combinations of anti-MRSA drugs such as vancomycin and the combination of traditional Chinese medicine and nanotechnology with antibiotics so as to provide reference for clinical medication and subsequent development of new drugs and new technology.
